This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Zoetis Stock Rises 15% in 3 Months: Time to Add to Your Portfolio?
by Zacks Equity Research
ZTS' innovative pet care products, along with efforts to expand the business, are expected to fuel significant growth in the future.
ILMNPositive Net Change ZTSPositive Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
by Zacks Equity Research
NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.
NVSPositive Net Change PFEPositive Net Change LLYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
by Zacks Equity Research
NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.
BMYPositive Net Change MRKPositive Net Change ILMNPositive Net Change NCNANegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Ball (BALL) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
BALLPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
by Zacks Equity Research
ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.
GSKPositive Net Change ILMNPositive Net Change FULCPositive Net Change ZNTLPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Company News for Sep 17, 2024
by Zacks Equity Research
Companies In The News Are: INTC, BA, NUVL, AA.
BAPositive Net Change INTCPositive Net Change AANegative Net Change NUVLNegative Net Change
aerospace biotechnology industrial-products semiconductor
Incyte Announces Promising New Data on Oncology Candidate at ESMO
by Zacks Equity Research
INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dependency.
INCYPositive Net Change SNDXPositive Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
by Zacks Equity Research
REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change
biotechnology biotechs medical pharmaceuticals
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
by Zacks Equity Research
Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.
ILMNPositive Net Change KRYSNegative Net Change FULCPositive Net Change IMRXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
by Zacks Equity Research
The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.
NVSPositive Net Change RHHBYPositive Net Change LLYPositive Net Change
biotechnology immuno-therapy medical pharmaceuticals
Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
by Zacks Equity Research
GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.
GSKPositive Net Change GILDNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs pharmaceuticals
Should You Buy Air Industries (AIRI) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
AIRIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study
by Zacks Equity Research
AURA stock up as lead candidate shows tumor control and visual acuity preservation abilities in eye cancer patients over 12 months of treatment.
ILMNPositive Net Change KRYSNegative Net Change FULCPositive Net Change AURANegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
by Zacks Equity Research
Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.
GSKPositive Net Change SMMTPositive Net Change IMVTPositive Net Change RLAYPositive Net Change TERNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy
by Zacks Equity Research
NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
by Ahan Chakraborty
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
NVSPositive Net Change RHHBYPositive Net Change PFEPositive Net Change LLYPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Lifeway Foods (LWAY) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
LWAYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Modiv Industrial, Inc. (MDV) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MDVNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, The Cooper Companies (COO)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
COONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?
by Zacks Equity Research
BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to be over-optimistic at this point and look before they leap.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
by Zacks Equity Research
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.
BMYPositive Net Change MRKPositive Net Change CRVSPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
by Zacks Equity Research
TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change TERNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Relay Stock Soars on Upbeat Data From Breast Cancer Study
by Zacks Equity Research
RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.
AZNPositive Net Change NVSPositive Net Change PFEPositive Net Change RLAYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg
by Zacks Equity Research
BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg.
REGNPositive Net Change NVSPositive Net Change LLYPositive Net Change BAYRYPositive Net Change
biotechnology pharmaceuticals
Why you Should Buy the 200-day Dip in ARM, MSTR, VKTX
by Andrew Rocco
The 200-day moving average can provide some of the best long-term entry points. MicroStrategy, Coinbase, and Viking Therapeutics offer high reward-to-risk as they retreat to an important technical level.
NVOPositive Net Change LLYPositive Net Change ARMNegative Net Change QQQNegative Net Change MSTRNegative Net Change VKTXNegative Net Change COINNegative Net Change BITFNegative Net Change
artificial-intelligence biotechnology bitcoin